Cantor Fitzgerald Sticks to Their Buy Rating for Vanda (VNDA)
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vanda yesterday and set a price target of $11.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brayer covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics, BioMarin Pharmaceutical, and Insmed. According to TipRanks, Brayer has an average return of 7.5% and a 45.31% success rate on recommended stocks.
In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
Based on Vanda’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $56.26 million and a GAAP net loss of $22.59 million. In comparison, last year the company earned a revenue of $47.65 million and had a GAAP net loss of $5.32 million
Read More on VNDA:
Disclaimer & DisclosureReport an Issue
- Vanda Pharmaceuticals: Promising Pipeline and Regulatory Progress Drive Buy Rating
- Vanda Pharmaceuticals announces submission of BLA to FDA for imsidolimab
- FDA Lifts Hold on Vanda’s Tradipitant Trials
- FDA lifts partial clinical hold on Vanda Pharmaceuticals’ tradipitant
- Vanda Pharmaceuticals: Buy Rating Backed by Promising Drug Pipeline and Market Potential
